RVNC has not yet lowered the price of Daxxify to procedural parity with Botox—i.e. $110 for an on-label glabellar-lines procedure—except for practices ordering >=150 vials. So, RVNC may still have more work to do on pricing, IMO.
On the Investor Day webcast, RVNC claimed to have lowered the price of Daxxify to parity with Botox, but this is only a half-truth, as far as I can tell.
Market Data 
Markets 
AI
